Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
Oyster Point Pharma, Inc. (OYST) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/13/2023 8-K/A Resignation/termination of a director
01/03/2023 8-K Resignation/termination of a director
Docs: "Second Amended and Restated Certificate of Incorporation of Oyster Point Pharma, Inc.",
"Second Amended and Restated Bylaws of Oyster Point Pharma, Inc."
11/10/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
11/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris • Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share"
08/11/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "###"
02/24/2022 8-K Quarterly results
01/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/04/2021 8-K Quarterly results
Docs: "Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights"
10/19/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "WAIVER AND AMENDMENT"
10/18/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CREDIT AGREEMENT AND GUARANTY",
"Oyster Point Pharma Announces FDA Approval of"
08/05/2021 8-K Quarterly results
08/02/2021 8-K Quarterly results
07/01/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "July 1, 2021 Investor Slide Presentation",
"Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 and OC-02 Against of SARS-CoV-2 Virus and Variants"
06/09/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/05/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
02/18/2021 8-K Quarterly results
12/18/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease"
12/02/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis"
11/05/2020 8-K Investor presentation
Docs: "November 2020 Investor Presentation",
"November 2020 Investor Presentation"
11/05/2020 8-K Quarterly results
Docs: "Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights"
10/09/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
06/05/2020 8-K Submission of Matters to a Vote of Security Holders
05/15/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock PRINCETON, N.J., May 15, 2020 — Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the pricing of its underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $28.00 per share. All of the shares are being offered by Oyster Point Pharma. The gross proceeds to Oyster Point Pharma from the offering, before deducting underwriting discounts and commissions and estimated offering expenses to be payable by Oyster Point Pharma, are expected to be $105.0 million. The offering is expected to close on May 19, 2020 su..."
05/11/2020 8-K Other Events
Docs: "OYSTER POINT PHARMA ANNOUNCES POSITIVE RESULTS IN ONSET-2 PHASE 3 TRIAL OF OC-01 NASAL SPRAY FOR THE TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE",
"Copy of Phase 3 ONSET-2 Trial Top-line Data Presentation"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy